News & Investors

Want to stay updated? Subscribe to our newsletters. For free.

Have questions? Our live support would be happy to help you.

Category: Insider Information

Epigenomics’ Partner BioChain Successfully Completes Clinical Validation Study for CFDA Approval of Epi proColon® in China

Berlin (Germany), Germantown, MD, and Newark, CA (U.S.A.), Beijing (China) – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), and BioChain Institute Inc. (BioChain), today announced that BioChain has completed its major clinical validation study to validate Epigenomics’ blood-based Septin9 screening assay Epi proColon® for the early detection of colorectal cancer (CRC) with the goal […]

Read more

Epigenomics AG: FDA Advisory Committee Provides Recommendations for Epigenomics’ Colorectal Cancer Screening Blood Test

PDF 45 KB   FDA Advisory Committee votes favorably that the benefits of Epi proColon® outweigh the risks Berlin (Germany) and Germantown, MD (U.S.A.), March 27, 2014 – Epigenomics AG (ISIN: DE000A1K0516, OTCQX: EPGNY) today announced the outcome of a meeting of the Molecular and Clinical Genetics Panel of FDA’s Medical Devices Advisory Committee held […]

Read more

Ad hoc: Epigenomics AG Announces FDA Advisory Committee Meeting to Review Epi proColon®

Berlin, Germany – Epigenomics AG (ISIN: DE000A1K0516) announces that the Company was informed by the U.S. Food and Drug Administration (FDA) via the premarket approval (PMA) review process for Epi proColon® that the Meeting of the Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee has been tentatively scheduled for Tuesday, March 25th, […]

Read more

Ad hoc: Epigenomics AG issues EUR 500,000 in convertible bonds to Yorkville

Berlin, Germany – Epigenomics AG (ISIN: DE000A1K0516, OTC: EPGNY) announces today that the Company successfully issued convertible bonds with a nominal amount of EUR 500,000 to YA Global Master SVP Ltd. (“Yorkville”) excluding pre-emptive rights to existing shareholders. The bonds were issued at 95% of their nominal amount, carry no interest, have a term until […]

Read more

Correction Notification: Ad Hoc Announcement Pursuant to §15 WpHG (German Securities Trading Act) Correction of the announcement: Epigenomics AG increases share capital

PDF 29 KB   Correction notifaction of the announcement of Epigenomics AG (Frankfurt Prime Standard: ECX; ISIN: DE000A1K0516) according to § 15 WpHG as of October 28, 2013 – 9:00 pm CET Epigenomics erroneously announced yesterday its intention to increase its share capital by up to EUR 4,136,720.00 from the authorized capital. Instead, Epigenomics plans […]

Read more

Ad Hoc Epigenomics AG successfully completes private placement of newly issued shares

PDF 28 KB   Not for distribution in the United States Berlin, Germany, October 29, 2013 – Today the Executive Board of Epigenomics AG (Frankfurt Prime Standard: ECX;ISIN: DE000A1K0516) with the approval of the Supervisory Board has resolved on the increase of the Company’s share capital by EUR 660,260.00 from the authorized capital 2013/I against […]

Read more